Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10 Return on Equity

Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10 (CYCCP) currently reports a ROE of -22.34%. That is below the Healthcare sector average of 20.86%. Use the charts on this page to explore Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10's ROE history and peer comparisons.

Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10's ROE of -22.34% is lower than the Healthcare sector average of 20.86%. That is roughly 207.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10's current -22.34% should be judged against Healthcare norms (sector average: 20.86%) and against CYCCP's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -22.34%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 20.86%. From there, open related valuation or income-statement pages for Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10, and consider following CYCCP for alerts when major investors trade the stock.

Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10 is classified in the Healthcare sector. On ROE, it currently shows -22.34% versus a sector average near 20.86%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CYCCP with unrelated industries.